94 related articles for article (PubMed ID: 18442267)
1. Cardiotoxic effects of antihistamines: from basics to clinics (...and back).
Soldovieri MV; Miceli F; Taglialatela M
Chem Res Toxicol; 2008 May; 21(5):997-1004. PubMed ID: 18442267
[TBL] [Abstract][Full Text] [Related]
2. Potential cardiac toxicity of H1-antihistamines.
Yap YG; Camm AJ
Clin Allergy Immunol; 2002; 17():389-419. PubMed ID: 12113224
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. [The importance of electrocardiography in the development of new drugs--prolonged QT intervals as indicators of adverse effects].
Jerie P; Vít P
Vnitr Lek; 2002 Dec; 48 Suppl 1():114-9. PubMed ID: 12744031
[TBL] [Abstract][Full Text] [Related]
5. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis.
Dumotier BM; Deurinck M; Yang Y; Traebert M; Suter W
Pharmacol Ther; 2008 Aug; 119(2):152-9. PubMed ID: 18462801
[TBL] [Abstract][Full Text] [Related]
6. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates.
Gwathmey JK; Tsaioun K; Hajjar RJ
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):647-60. PubMed ID: 19442031
[TBL] [Abstract][Full Text] [Related]
7. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
[TBL] [Abstract][Full Text] [Related]
8. Detection and reporting of drug-induced proarrhythmias: room for improvement.
Darpö B
Europace; 2007 Sep; 9 Suppl 4():iv23-36. PubMed ID: 17766321
[TBL] [Abstract][Full Text] [Related]
9. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
10. Systematic screening for pharmacokinetic interactions during drug development.
Fuhr U; Weiss M; Kroemer HK; Neugebauer G; Rameis H; Weber W; Woodcock BG
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):139-51. PubMed ID: 8861732
[TBL] [Abstract][Full Text] [Related]
11. Chemical process research and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective.
Federsel HJ
Acc Chem Res; 2009 May; 42(5):671-80. PubMed ID: 19338294
[TBL] [Abstract][Full Text] [Related]
12. [Cardiovascular risk stratification. Systolic, diastolic or pulse pressure?].
Pede S; Lombardo M
Ital Heart J Suppl; 2001 Apr; 2(4):356-8. PubMed ID: 19397006
[TBL] [Abstract][Full Text] [Related]
13. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation.
Wang D; Patel C; Cui C; Yan GX
Pharmacol Ther; 2008 Aug; 119(2):141-51. PubMed ID: 18423604
[TBL] [Abstract][Full Text] [Related]
14. Rare complications of diphenhydramine toxicity.
Ramachandran K; Sirop P
Conn Med; 2008 Feb; 72(2):79-82. PubMed ID: 18306834
[TBL] [Abstract][Full Text] [Related]
15. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
Stevens JL
Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
[TBL] [Abstract][Full Text] [Related]
16. Gene-specific therapy for inherited arrhythmogenic diseases.
Napolitano C; Bloise R; Priori SG
Pharmacol Ther; 2006 Apr; 110(1):1-13. PubMed ID: 16168489
[TBL] [Abstract][Full Text] [Related]
17. Psychiatric manifestations of medications commonly prescribed in otolaryngology.
Levy S; Abaza MM; Hawkshaw MJ; Sataloff RT
Ear Nose Throat J; 2001 Apr; 80(4):266-8, 270-1. PubMed ID: 11338652
[TBL] [Abstract][Full Text] [Related]
18. Energy balance, physical activity, and cancer risk.
Fair AM; Montgomery K
Methods Mol Biol; 2009; 472():57-88. PubMed ID: 19107429
[TBL] [Abstract][Full Text] [Related]
19. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?
Shah RR
Pharmacol Ther; 2008 Aug; 119(2):215-21. PubMed ID: 18455801
[TBL] [Abstract][Full Text] [Related]
20. Sleep complaints: Whenever possible, avoid the use of sleeping pills.
Prescrire Int; 2008 Oct; 17(97):206-12. PubMed ID: 19536941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
